Polar Asset Management Partners’s Syndax Pharmaceuticals SNDX Stock Holding History

Polar Asset Management Partners’s Portfolio SNDX Stock Details SNDX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q3	–	Sell	-97,113	Closed	-$909K	–	794
2025 Q2	$909K	Sell	97,113 -9,515	-9%	-$105K	0.01%	379
2025 Q1	$1.31M	Buy	106,628 +21,630	+25%	+$305K	0.03%	293
2024 Q4	$1.12M	Buy	+84,998	New	+$1.45M	0.01%	420
2024 Q1	–	Sell	-67,100	Closed	-$1.45M	–	863
2023 Q4	$1.45M	Buy	+67,100	New	+$1.03M	0.03%	401

Other funds holding SNDX

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

KCM

Kynam Capital Management Princeton, New Jersey $1.81B AUM 192.15% 1-Year Est. Return

Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Point72 Asset Management Stamford, Connecticut $90.7B AUM 77.13% 1-Year Est. Return

State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return

Eversept Partners New York $1.93B AUM 160.8% 1-Year Est. Return

Adage Capital Partners Boston, Massachusetts $71.3B AUM 56.8% 1-Year Est. Return

KCM

Kingdon Capital Management New York $976M AUM 66.76% 1-Year Est. Return

Polar Asset Management Partners's SNDX Position: Q3 2025 in Review

Polar Asset Management Partners sold out of Syndax Pharmaceuticals (SNDX) in Q3 2025, closing a stake of 97,113 shares — an estimated $909K sold.

Polar Asset Management Partners first reported a position in SNDX in Q4 2023 and held it in 4 quarters. The position peaked at $1.45M in Q4 2023. 227 funds tracked by Wall St. Rank hold SNDX as of Q3 2025.

Polar Asset Management Partners reported no remaining Syndax Pharmaceuticals position as of Q3 2025 after selling out during the quarter.
Polar Asset Management Partners sold 97,113 Syndax Pharmaceuticals shares in Q3 2025, an estimated $909K.
Polar Asset Management Partners first reported a position in Syndax Pharmaceuticals in Q4 2023 and held it in 4 quarters.
Polar Asset Management Partners's Syndax Pharmaceuticals position peaked at $1.45M in Q4 2023.
227 funds tracked by Wall St. Rank held Syndax Pharmaceuticals as of Q3 2025.

Based on Polar Asset Management Partners's 13F filing for Q3 2025, filed 14 Nov 2025.